T. Rowe Price Investment Management Inc. Acquires 118,014 Shares of Abbott Laboratories $ABT

by · The Cerbat Gem

T. Rowe Price Investment Management Inc. raised its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,887,109 shares of the healthcare product maker’s stock after acquiring an additional 118,014 shares during the period. Abbott Laboratories comprises about 1.4% of T. Rowe Price Investment Management Inc.’s investment portfolio, making the stock its 10th largest holding. T. Rowe Price Investment Management Inc. owned about 1.03% of Abbott Laboratories worth $2,241,076,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares in the last quarter. United Bank boosted its stake in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC raised its holdings in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after purchasing an additional 292,547 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

ABT has been the subject of several recent analyst reports. Bank of America cut their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Sanford C. Bernstein decreased their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Barclays lowered their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Mizuho reduced their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, UBS Group decreased their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $118.30.

View Our Latest Analysis on Abbott Laboratories

Insiders Place Their Bets

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Down 0.0%

Shares of Abbott Laboratories stock opened at $88.48 on Friday. The firm’s 50-day moving average price is $90.39 and its two-hundred day moving average price is $106.73. The company has a market capitalization of $154.12 billion, a price-to-earnings ratio of 24.78, a PEG ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).